Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, Brenda R. Hemmelgarn, Adeera Levin, Merlin C. Thomas, Christoph Wanner, Bertram L. Kasiske, David C. Wheeler, Per Henrik Groop, George L. Bakris, Mark E. Cooper, Dong Wan Chae, Michael H. Davidson, Ian H. de Boer, Dick de Zeeuw, Alessia Fornoni, Luigi Gnudi, Charles A. Herzog, Adriana M. HungTazeen Hasan Jafar, Meg Jardine, Vivekanand Jha, Linong Ji, Steven E. Kahn, Robyn G. Langham, Edgar V. Lerma, Ronald C.W. Ma, Hirofumi Makino, Michel Marre, Michael Mauer, Kaj Metsärinne, Robert G. Nelson, Roberto Pecoits-Filho, Carol A. Pollock, Mohan Rajapurkar, Peter Rossing, Ivan Rychlík, Kumar Sharma, Robert C. Stanton, Vladimír Tesař, Ilkka Tikkanen, Charlie R.V. Tomson, Robert D. Toto, Yusuke Tsukamoto, Katherine R. Tuttle, Takashi Wada, Winfred W. Williams, Hong Zhang, Sophia Zoungas

Research output: Contribution to journalArticlepeer-review

78 Scopus citations


The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.

Original languageEnglish (US)
Pages (from-to)1175-1183
Number of pages9
JournalKidney international
Issue number6
StatePublished - Dec 1 2016

Bibliographical note

Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from AbbVie, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Fresenius Medical Care, Janssen, Merck, Roche, Takeda, and ZS Pharma.

Funding Information:
VP declared having received consultancy fees from Abbvie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Novo Nordisk, Pharmalink, Relypsa, and Servier; speaker honoraria from International Diabetes Federation, Pfizer, and Sanofi; and research support from Abbvie, Jannsen and Pfizer. All monies were given to The George Institute. RA declared having received consultancy fees from Abbvie, Bayer, Celgene, Daiichi Sankyo, Janssen, and Takeda, and research support from the National Heart, Lung, and Blood Institute and Veterans Administration. MCT declared having received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Eli Lilly, and speaker honoraria from AstraZeneca, BGP, Boehringer Ingelheim, Eli Lilly, Merck Sharpe & Dohme, Novartis, and Servier. CW declared having received consultancy fees from Boehringer Ingelheim and Janssen and speaker honoraria from Boehringer Ingelheim. DCW declared having received consultancy fees from Akebia, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Otsuka, UCB Celltech, and Vifor; speaker honoraria from Amgen, Fresenius, Janssen, Vifor, and ZS Pharma; and research support from British Heart Foundation, Healthcare Quality Improvement Partnership, Kidney Research UK, National Institute for Health Research, and Australian National Health & Medical Research Council. All the other authors declared no competing interests.

Publisher Copyright:
© 2016 International Society of Nephrology


  • antidiabetic agents
  • cardiovascular disease
  • chronic kidney disease
  • diabetes
  • glycemic control
  • renoprotection


Dive into the research topics of 'Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference'. Together they form a unique fingerprint.

Cite this